Punjab Samachar

Postpartum Depression Market

DelveInsight’s Postpartum Depression (PPD) – Market Insights, Epidemiology and Market Forecast – 2030report delivers an in-depth understanding of the Postpartum Depression (PPD), historical and forecasted epidemiology as well as the Postpartum Depression (PPD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Postpartum Depression (PPD) market report provides current treatment practices, emerging drugs, and market share of individual therapies, current and forecasted 7MM Postpartum Depression (PPD) market size from 2018 to 2030. The report also covers current Postpartum Depression (PPD) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Some of the key facts of the Postpartum Depression Market Report:

• In the EU5 countries the diagnosed prevalence of Postpartum Depression was found to be maximum in France with 99,815 cases, followed by the United Kingdom with 99,520 cases in 2020. While, the least number of cases were found in Spain, i.e., 57,396 in 2020.
• In Japan, the diagnosed prevalence of Postpartum Depression was found to be 118,386 in 2020, resulting into the second highest after the US across the 7MM.
• According to the American College of Obstetricians and Gynecologists, It is estimated that 14–23% of pregnant women experience depression during pregnancy, and 5–25% experience depression postpartum.  

Key Benefits of the Postpartum Depression (PPD) Report:

• The report covers a descriptive overview of Postpartum Depression (PPD), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the Postpartum Depression (PPD) epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Postpartum Depression (PPD) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Postpartum Depression (PPD) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Postpartum Depression (PPD) market.

Got queries? Click here to know more about the Postpartum Depression Market Landscape

Postpartum Depression Overview

Postpartum depression (PPD) is the most common non-psychotic, complication of childbearing affecting approximately 10-15% of women and as such, represents a considerable public health problem affecting women and their families. The postnatal period is well established as an increased time of risk for the development of serious mood disorders. 

There are three common forms of postpartum affective illness: the blues (baby blues, maternity blues), postpartum (or postnatal) depression, and puerperal (postpartum or postnatal) psychosis each of which differs in its prevalence, clinical presentation, and management. While postpartum depression mainly affects the mother, fathers may also exhibit signs of paternal postpartum depression. 

This condition may come on more gradually in men within the first 12 months of a child’s life as opposed to women who experience it sooner. Postpartum depression usually begins within 1–12 months after delivery. In some women, post-partum blues simply continue and become more severe. In others, a period of well-being after delivery is followed by a gradual onset of depression. 

The patterns of symptoms in women with postpartum depression are similar to those in women who have depression unrelated to childbirth. The common symptoms observed during PPD include tearfulness, despondency, emotional liability, feelings of guilt, loss of appetite, and sleep disturbances, feeling moody, irritable, or restless, poor concentration and memory, etc. 

Postpartum Depression Epidemiological Insights:

• According to the Centers for Disease Control and Prevention (CDC), depression is a common and serious disorder. A study by CDC showed that about 1 out of 10 women in the United States experience symptoms of depression.  Also, by using the Pregnancy Risk Assessment Monitoring System (PRAMS), CDC research showed that nationally, about 1 in 9 women experience symptoms of postpartum depression. 
• A study conducted by Slomian et al. (2019) found that PPD prevalence varied between 0.5% and 60% among countries, as estimated by the self-reported 10-item EPDS questionnaire. The prevalence of PPD varies from 1.9% to 82.1% in developed countries, with the lowest prevalence reported in Germany and the highest prevalence in the United States.
• The aspect of the types of PPD cited by Postpartum Depression.org, it was found that Postpartum Obsessive-Compulsive Disorder (OCD), Postpartum Panic Disorder, and Postpartum Onychomycosis  can be seen in 3–5%, up to 10%, and over 9% of postpartum women, respectively. .

Postpartum Depression Epidemiological Segmentation 

• Total Postpartum Depression Prevalent Population 
• Total Postpartum Depression Type-specific Diagnosed Prevalence 

Postpartum Depression Market Outlook 

According to the American Psychiatric Association (APA), Postpartum depression (PPD) is a serious, but treatable medical illness, which involves feelings of extreme sadness, emotional liability, indifference and/or anxiety, as well as changes in energy, sleep, and appetite, and carries risks for the mother and the newborn child. PPD usually starts within the first month or any time within the first year after childbirth and can last from weeks to months. In more severe cases, it can develop into chronic episodes of depression.

 Treatments include antidepressant medications along with the new upcoming therapeutic strategies that work on the principle of GABAA receptor modulation. The medical management for PPD comprises several aspects such as interventions for depression, anxiety disorders, alcohol and drug abuse, and psychological interventions for eating disorders. The treatment strategy also encompasses psychological and psychosocial treatments, as well as non-pharmacologic treatments. Besides, the medical care of a PDD patient and his family is incomplete without providing a support system for their psychosocial well-being. The current US market consists of only one approved product—Zulresso (brexanolone/SAGE-547)—to treat patients with PPD.

Learn more by requesting for sample @ Postpartum Depression Market Trends

Postpartum Depression Key Companies

• Sage Therapeutics 
• Lipocine
• Brii Biosciences 
• And many others

 Postpartum Depression Therapies

•  Zuranolone (SAGE-217) 
• LPCN 1154
• BRII-296
• And many others 

    Postpartum Depression Market Drivers 

•     Increasing Cases of Postpartum Depression 
•     Increasing Awareness of Postpartum Depression
•     An improvement over Conventional Therapies

Postpartum Depression Market Barriers 

• Adverse Side Effects Associated With Current Therapy
• Underdiagnosis and Undertreatment
• Lack of Proper Diagnostic Tools
• Lack of Patient Compliance

Table of Contents

• Key Insights 
• Report Introduction 
• Executive Summary of Postpartum Depression  
• Disease Background and Overview
• Epidemiology and patient population
• Postpartum Depression Emerging Therapies
• Postpartum Depression  Market Outlook
• Market Access and Reimbursement of Therapies
• Appendix
• Postpartum Depression  Report Methodology
• DelveInsight Capabilities
• Disclaimer
• About DelveInsight

Click here to read more about Postpartum Depression Market Insight

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/